Dear Partners and Clients, As we wrap up 2024, we want to take a moment to reflect on what an exciting and fruitful year it has been for amofor. Together with our partners, we’ve made tremendous strides in advancing in-silico formulation development and pushing the boundaries of pharmaceutical science. Our continued efforts to develop better […]

Release profiles are at the heart of successful formulations. However, drug formulation scientists struggle with them. Weeks of trial-and-error experiments. Unpredictable outcomes. No mechanistic understanding.amofor is now changing this. Formulators can use a drug release forecasting tool that delivers unprecedented accuracy, enabling better formulations in record time and at reduced cost. The Challenge of ASD

Physics-based simulations enhance the precision of pharmaceutical drug formulation. This blog presents a proof-of-principle study conducted in collaboration between amofor and Boehringer Ingelheim. This project aimed to evaluate the feasibility of shifting from spray-drying to hot-melt extrusion (HME) in producing amorphous solid dispersions (ASDs), focusing on in vitro and in vivo performance comparisons. Traditionally, spray-drying

This October amofor is making our debut at the AIChE Annual Meeting in San Diego. From October 27 to 31, 2024, we will join thousands of professionals at the world’s largest chemical engineering conference to shape the future of drug formulation. We look forward to connecting with drug formulators and industry professionals! Why Attend AIChE and Connect with amofor?

In the last five years, amofor has rapidly transformed from a German academic start-up to a highly innovative force revolutionizing drug formulation with physics-based in silico modeling. On this occasion, the two founders, Christian Lübbert and Gabriele Sadowski, shed some light on the origins and driving forces behind amofor. Who is behind this company, and what

Artificial intelligence (AI) and machine learning approaches have flooded many industries with the promise of groundbreaking advances. But can these technologies also meet the complex demands of drug formulation? In this blog post, we debunk common myths surrounding AI in drug formulation and show why physical simulations are still a suitable and state-of-the-art technique to formulate drugs. Decoding Machine Learning in Drug Formulation

Amorphous solid dispersions (ASDs) are crucial in enhancing the solubility and stability of water-insoluble drugs, maximizing therapeutic efficacy. This blog presents a shelf life study of ASD formulations under long-term storage conditions. The study demonstrates the power of integrating physics-based simulations with experimental data. It is one of the few publications combining theoretical work with

amofor is pleased to participate at the 8th annual SOS conference in Barcelona, taking place on May 13-14, 2024. It’s a highly interactive international conference, organized by FreeThink Technologies, Inc and Lhasa Limited. The event focuses on the latest discoveries and innovations in stability science. It dives deep into both chemical and physical stability issues

Drug formulation can feel like a game of chess. Each move is critical. The outcome is uncertain, reflecting the unpredictability of formulation experiments. This dynamic leads to a constant cycle of trial and error. At amofor, we develop a so-called “digital twin” of the formulation. It works like a grandmaster-level chess advisor. It provides clarity

In the preclinical phase, formulation development is usually very standardized, limited in time and follows heuristic guidelines. The digital design approach to drug formulation developed by amofor offers a unique alternative for customers looking for more efficient approaches. This innovative method enables the development of highly potent preclinical formulations in just one day, allowing a